We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $162M
1-Year Est. Return 259.04%
This Fund
S&P 500
This Quarter Est. Return
+10.44%
1 Year Est. Return
+259.04%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$22M
Cap. Flow
-$6.18M
Cap. Flow %
-4.6%
Top 10 Hldgs %
36.29%
Holding
86
New
27
Increased
9
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$4.06M
2
VSTM icon
Verastem
VSTM
+$3.76M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$2.25M
4
APLS
Apellis Pharmaceuticals
APLS
+$1.83M
5
UHS icon
Universal Health Services
UHS
+$1.82M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$3.47M
2
VRDN icon
Viridian Therapeutics
VRDN
+$2.93M
3
SVRA icon
Savara
SVRA
+$2.32M
4
AZN icon
AstraZeneca
AZN
+$2.28M
5
ANAB icon
AnaptysBio
ANAB
+$2.13M

Sector Composition

Rank Sector Weight
1 Healthcare 79.82%
2 Miscellaneous 20.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$20.5B
$7.35M 5.47%
+200,000
New +$55.7M
BBIO icon
2
BridgeBio Pharma
BBIO
$14.6B
$6.72M 4.99%
155,533
-9,963
-6% -$362K
GH icon
3
Guardant Health
GH
$21.7B
$5.11M 3.8%
98,182
-29,000
-23% -$1.3M
GERN icon
4
Geron
GERN
$1.01B
$4.81M 3.58%
3,414,377
+198,920
+6% +$282K
IONS icon
5
Ionis Pharmaceuticals
IONS
$9.65B
$4.79M 3.56%
121,116
-14,500
-11% -$475K
THC icon
6
Tenet Healthcare
THC
$21.3B
$4.75M 3.53%
+27,000
New +$4.06M
AZN icon
7
PUT
AstraZeneca
AZN
$252B
$3.93M 2.92%
+14,181
New +$1.99M
COGT icon
8
Cogent Biosciences
COGT
$6.03B
$3.83M 2.85%
533,647
-88,031
-14% -$488K
CYTK icon
9
Cytokinetics
CYTK
$10.1B
$3.83M 2.85%
115,817
+12,334
+12% +$429K
REPL icon
10
Replimune Group
REPL
$1.42B
$3.7M 2.75%
397,846
+103,000
+35% +$899K
LLY icon
11
Eli Lilly
LLY
$1.02T
$3.64M 2.71%
4,673
– –
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$3.49M 2.59%
41,641
-1,800
-4% -$135K
ISRG icon
13
Intuitive Surgical
ISRG
$130B
$3.46M 2.57%
6,358
– –
IRON icon
14
Disc Medicine
IRON
$3.04B
$3.25M 2.42%
61,356
-300
-0.5% -$14.1K
NTRA icon
15
Natera
NTRA
$47.3B
$3.15M 2.34%
18,650
– –
AKRO
16
PUT
DELISTED
Akero Therapeutics
AKRO
$3.13M 2.32%
+58,579
New +$2.66M
FULC icon
17
Fulcrum Therapeutics
FULC
$294M
$3.06M 2.28%
444,949
-244,188
-35% -$1.31M
SRRK icon
18
Scholar Rock
SRRK
$6.74B
$2.99M 2.22%
84,339
– –
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.84B
$2.89M 2.15%
308,298
-28,900
-9% -$318K
VSTM icon
20
Verastem
VSTM
$743M
$2.49M 1.85%
+599,900
New +$3.76M
PRAX icon
21
Praxis Precision Medicines
PRAX
$9.82B
$2.48M 1.84%
+59,002
New +$2.25M
PEN icon
22
Penumbra
PEN
$12.7B
$2.31M 1.72%
9,000
– –
ETNB
23
DELISTED
89bio
ETNB
$2.29M 1.7%
233,426
-120,456
-34% -$997K
TVTX icon
24
Travere Therapeutics
TVTX
$6.15B
$2.27M 1.69%
153,278
+35,261
+30% +$584K
CNTA
25
DELISTED
Centessa Pharmaceuticals
CNTA
$2.19M 1.63%
166,944
+24,200
+17% +$307K
1
2 3 4

Similar funds

STCOSD
Sageworth Trust Company of South Dakota Sioux Falls, South Dakota $162M AUM 26.79% 1-Year Est. Return
CCA
Cruiser Capital Advisors Stamford, Connecticut $162M AUM 78.28% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return
CFG
Cornerstone Financial Group Omaha, Nebraska $162M AUM 14.64% 1-Year Est. Return
TF
TME Financial Huntington Beach, California $162M AUM 16.23% 1-Year Est. Return
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return

Exome Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Exome Asset Management held 86 positions worth $135M, up 20% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Exome Asset Management withdrew a net $6.18M in Q2 2025, closing 23 positions and reducing 17 holdings. Its most notable exit was Akero Therapeutics, an estimated $3.47M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Exome Asset Management opened a new position in Tenet Healthcare worth $4.75M.

  • Exome Asset Management's largest Q2 2025 buy was Tenet Healthcare: 27,000 shares worth $4.75M.
  • Exome Asset Management added most to BioCryst Pharmaceuticals in Q2 2025, an estimated $1.05M increase.
  • Exome Asset Management's biggest Q2 2025 reduction was AnaptysBio, cutting an estimated $2.13M.
  • Exome Asset Management fully exited Akero Therapeutics in Q2 2025, selling an estimated $3.47M.
  • Exome Asset Management's ten largest holdings make up 36% of its $135M portfolio in Q2 2025.
  • Exome Asset Management opened 27 new positions and closed 23 in Q2 2025.
  • Exome Asset Management's portfolio value rose 20% quarter-over-quarter to $135M.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.